Ginkgo completes acquisition of Zymergen

Ginkgo Bioworks/Ginkgo Automation and Datapoints

Ginkgo completed its acquisition of Zymergen on 19 October 2022, folding Zymergen's lab automation, software and strain engineering teams into Ginkgo's cell-programming platform.

• All-stock transaction; Ginkgo delivered 99.4M Class A shares ($2.44/share) for ~$300M valuation.
• Zymergen brought automation, machine learning and strain-engineering expertise to scale Ginkgo's Foundry.
• Ginkgo's largest acquisition to date; integrated teams into cell-programming and DNA-synthesis infrastructure.
• Strategic rationale: biodesign scales through automation and software; acquisition avoided rebuild vs acquisition path.